Screener
Rhythm Pharmaceuticals, Inc. RYTM Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $62,137 | $54,301 |
| Short-term investments | 278,488 | 334,648 |
| Accounts receivable, net | 34,192 | 26,081 |
| Inventory | 28,651 | 25,753 |
| Prepaid expenses and other current assets | 26,622 | 26,133 |
| Total current assets | 430,090 | 466,916 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s cash & equivalents?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported cash & equivalents of $62.14M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s cash & equivalents changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s cash & equivalents decreased by 41.4% year-over-year, from $106.1M to $62.14M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Rhythm Pharmaceuticals, Inc.'s cash & equivalents has grown at a -11.6% compound annual growth rate (CAGR), from $100.85M to $54.3M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude